華衆車載(06830.HK)與寧波方澤科技擬設合營拓金屬粉末注塑成型業務
華衆車載(06830.HK)公佈,附屬公司寧波華衆與獨立協力廠商寧波方澤科技達成協議,共同投資設立合營公司,分別持有合營公司40%及60%股權。合營公司將主要從事金屬粉末注塑成型(MIM)項目及金屬3D增材製造業務。
項目一期投資總額約爲1億元人民幣(下同),建設完成後,生產規模以MIM產品爲主計算,目標三年內達到年產值約幣1.5億元。另外,項目將成建成金屬3D增材製造工藝中心,爲金屬3D增材製造產業化做好準備。
而項目建設二期預計總投資爲2億元,計劃在未來5年內建成。項目完成後預計年產值達5億元,合營公司將成爲國際領先的粉末冶金/粉末注射成型/金屬增材製造高新科技企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.